Publication showcases the capabilities of Insilico's advanced generative AI platform and integrated workflow in facilitating the rapid development of ISM5939, further demonstrating the potential of AI ...
Researchers from artificial intelligence (AI) drug developer Insilico Medicine and two partner institutions have published a study concluding that its lead candidate ISM001-055 is the first to show ...
CAMBRIDGE, Mass., Dec. 2, 2025 /PRNewswire/ -- Insilico Medicine ("Insilico"), a global leader in AI-powered drug discovery, and Atossa Therapeutics ("Atossa") (Nasdaq: ATOS), a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback